Marshall Wace
RLMD icon

Marshall Wace’s Relmada Therapeutics RLMD Stock Holding History

Marshall Wace’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.2M Buy
4,481,606
+1,291,944
+41% +$6.11M 0.03% 543
2025
Q4 		$15.4M Buy
3,189,662
+2,917,609
+1,072% +$9.78M 0.01% 724
2025
Q3 		$547K Buy
272,053
+117,485
+76% +$113K ﹤0.01% 2196
2025
Q2 		$92.7K Buy
+154,568
New +$79.3K ﹤0.01% 2551
2024
Q4 		– Sell
-50,570
Closed -$164K – 2940
2024
Q3 		$164K Sell
50,570
-106,049
-68% -$343K ﹤0.01% 2318
2024
Q2 		$470K Sell
156,619
-51,251
-25% -$185K ﹤0.01% 1988
2024
Q1 		$967K Buy
207,870
+54,345
+35% +$262K ﹤0.01% 1665
2023
Q4 		$636K Buy
+153,525
New +$455K ﹤0.01% 1629
2022
Q4 		– Sell
-96,254
Closed -$3.56M – 3348
2022
Q3 		$3.56M Buy
+96,254
New +$2.67M 0.01% 1624

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Marshall Wace's RLMD Position: Q1 2026 in Review

Marshall Wace increased its Relmada Therapeutics (RLMD) stake by 41% in Q1 2026, buying an estimated $6.11M and bringing the position to 4,481,606 shares worth $31.2M. The position accounts for 0.03% of the portfolio, ranked #543.

Marshall Wace first reported a position in RLMD in Q3 2022 and has held it in 9 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Marshall Wace held 4,481,606 shares of Relmada Therapeutics worth $31.2M as of Q1 2026.
  • Marshall Wace bought 1,291,944 Relmada Therapeutics shares in Q1 2026, an estimated $6.11M.
  • Relmada Therapeutics made up 0.03% of Marshall Wace's portfolio in Q1 2026, its #543 holding.
  • Marshall Wace first reported a position in Relmada Therapeutics in Q3 2022 and has held it in 9 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.